See more : Exact Sciences Corporation (EXAS) Income Statement Analysis – Financial Results
Complete financial analysis of Senti Biosciences, Inc. (SNTI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senti Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bharat Bijlee Limited (BBL.BO) Income Statement Analysis – Financial Results
- Lin BioScience, Inc. (6696.TWO) Income Statement Analysis – Financial Results
- Futuris Company (FTRS) Income Statement Analysis – Financial Results
- Meshek Energy – Renewable Energies Ltd. (MSKE.TA) Income Statement Analysis – Financial Results
- Bank of Utica (BKUTK) Income Statement Analysis – Financial Results
Senti Biosciences, Inc. (SNTI)
About Senti Biosciences, Inc.
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.56M | 4.29M | 2.29M | 394.00K | 85.00K |
| Cost of Revenue | 5.24M | 3.92M | 3.01M | 15.96M | 14.52M |
| Gross Profit | -2.68M | 366.00K | -719.00K | -15.56M | -14.44M |
| Gross Profit Ratio | -104.76% | 8.54% | -31.38% | -3,949.75% | -16,987.06% |
| Research & Development | 32.15M | 34.07M | 21.96M | 15.96M | 14.52M |
| General & Administrative | 34.87M | 40.85M | 21.25M | 9.30M | 7.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.87M | 40.85M | 21.25M | 9.30M | 7.34M |
| Other Expenses | 27.69M | 12.42M | -470.00K | -172.00K | 0.00 |
| Operating Expenses | 95.29M | 74.92M | 42.74M | 25.09M | 7.39M |
| Cost & Expenses | 94.71M | 74.92M | 42.74M | 25.09M | 21.92M |
| Interest Income | 2.86M | 1.70M | 11.00K | 88.00K | 674.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.43M | 3.89M | 3.01M | 1.99M | 427.00K |
| EBITDA | -61.34M | -70.63M | -39.68M | -22.71M | -21.36M |
| EBITDA Ratio | -2,395.00% | -1,647.90% | -1,633.09% | -5,703.30% | -25,123.53% |
| Operating Income | -92.73M | -70.63M | -40.45M | -24.69M | -21.78M |
| Operating Income Ratio | -3,620.73% | -1,647.90% | -1,765.43% | -6,267.51% | -25,625.88% |
| Total Other Income/Expenses | 9.32M | 12.42M | -14.87M | 4.83M | 625.00K |
| Income Before Tax | -83.41M | -58.21M | -55.32M | -19.86M | -21.16M |
| Income Before Tax Ratio | -3,256.77% | -1,358.14% | -2,414.62% | -5,041.12% | -24,890.59% |
| Income Tax Expense | 0.00 | -12.42M | 11.00K | 150.00K | 0.00 |
| Net Income | -92.92M | -58.21M | -55.32M | -19.86M | -21.16M |
| Net Income Ratio | -3,628.23% | -1,358.14% | -2,414.62% | -5,041.12% | -24,890.59% |
| EPS | -16.01 | -22.29 | -12.67 | -4.55 | -1.56 |
| EPS Diluted | -16.01 | -22.29 | -12.67 | -4.55 | -1.56 |
| Weighted Avg Shares Out | 4.44M | 2.61M | 4.37M | 4.37M | 13.59M |
| Weighted Avg Shares Out (Dil) | 4.44M | 2.61M | 4.37M | 4.37M | 13.59M |
Senti Bio Announces New Employment Inducement Grants
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting
Best Penny Stocks to Buy in a Volatile Market? 3 to Watch Today
Best Penny Stocks To Buy Now? 3 To Watch As Stock Market Crash Continues
Senti Bio to Participate in Chardan's 6th Annual Genetic Medicines Conference
Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference
Chardan Announces Launch of ChEF (Chardan Equity Facility)
Senti Bio Reports Second Quarter Financial Results and Business Updates
Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
Synthetic Biology Platform Senti Bio Rides On Omid Farokhzad's SPAC For NASDAQ Debut
Source: https://incomestatements.info
Category: Stock Reports